VSN.L - Verseon Corporation

LSE - LSE Delayed Price. Currency in GBp
126.50
0.00 (0.00%)
At close: 4:30PM BST
Stock chart is not supported by your current browser
Previous Close126.50
Open127.50
Bid0.00 x 150000
Ask0.00 x 150000
Day's Range127.50 - 127.50
52 Week Range126.50 - 165.00
Volume8,000
Avg. Volume56,124
Market Cap191.56M
BetaN/A
PE Ratio (TTM)-9.73
EPS (TTM)-13
Earnings DateSep 8, 2017 - Sep 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire25 days ago

    Verseon Developing Oral Treatment for Hereditary Angioedema

    Verseon has announced the launch of a drug program developing oral treatments for hereditary angioedema , a rare, life-threatening genetic disease. In their interim report published yesterday, the Company presented data from a well-established HAE disease model which demonstrate the efficacy of their plasma kallikrein inhibitors in reducing swelling.

  • Verseon Reveals Preclinical Data on Novel Drug Candidates to Treat Diabetic Macular Edema
    Business Wire4 months ago

    Verseon Reveals Preclinical Data on Novel Drug Candidates to Treat Diabetic Macular Edema

    Verseon presented preclinical data on multiple novel drug candidates for the treatment of diabetic macular edema at the 2017 BIO International Conference in San Diego, last week.

  • We're sorry this is all we were able to find about this topic.